Terveystalo signed an agreement to acquire Hohde Group, comprising Hammas Hohde Oy and Loisto Laboratoriot Oy, in a transaction financed through debt committed by Terveystalo's existing partner banks. The acquisition is subject to approval by the Finnish Competition and Consumer Authority. The transaction directly supports Terveystalo's stated strategic objective of doubling its oral health business and becoming one of Finland's leading oral health companies, as communicated at its 2024 Capital Markets Day. Significant value creation is expected through growth and cost synergies, anticipated to materialise primarily within 36 months of closing. The transaction is expected to be earnings per share accretive from the first full year following completion.

HOHDE GROUP, which reported an EBITDA margin of LOGIN in 2025, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN discount to the average currently observed in the Healthcare & Pharma sector (13.3x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.